Cargando…
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
BACKGROUND: This phase II bridging study assessed the safety and efficacy of nab-paclitaxel/gemcitabine (Metastatic Pancreatic Adenocarcinoma Clinical Trial [MPACT] regimen) in Chinese patients with metastatic pancreatic cancer (MPC). METHODS: This 3-part sequential study evaluated nab-paclitaxel 12...
Autores principales: | Xu, Ruihua, Yu, Xianjun, Hao, Jihui, Wang, Liwei, Pan, Hongming, Han, Guohong, Xu, Jianming, Zhang, Yanqiao, Yang, Shujun, Chen, Jia, Ying, Jieer, Dai, Guanghai, Li, Mingyu, Begic, Damir, Lu, Brian, Shen, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740894/ https://www.ncbi.nlm.nih.gov/pubmed/29273007 http://dx.doi.org/10.1186/s12885-017-3887-z |
Ejemplares similares
-
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
por: Gharaibeh, M, et al.
Publicado: (2015) -
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020) -
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023) -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020) -
Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
por: Kamata, Ken, et al.
Publicado: (2023)